Taysha Gene Therapies announced that on April 1, 2026, its Compensation Committee granted four new employees a total of 300,000 restricted stock units and options to purchase 92,400 shares at an exercise price of $4.31. The grants were made under the company's 2023 Inducement Plan as part of their employment agreements.

Taysha Gene Therapies reported full-year 2025 net loss of $109.0 million and announced significant progress in its lead program TSHA-102 for Rett syndrome treatment. The company has dosed multiple patients in its REVEAL pivotal trial and received FDA clearance for the ASPIRE trial in younger patients (ages 2-4). TSHA-102 maintained a favorable safety profile with no treatment-related serious adverse events. The company expects to complete dosing in both trials by Q2 2026 and has secured FDA alignment on manufacturing and regulatory strategy for its planned BLA submission. Cash position stands at $319.8 million, sufficient to fund operations into 2028.

Taysha Gene Therapies announced that its Compensation Committee granted 349,000 restricted stock units to three new employees on February 2, 2026, as an inducement for employment. The RSUs will vest in four equal annual installments over four years, subject to continued service with the company.

The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.

Taysha Gene Therapies granted five new employees options to purchase 225,000 shares of common stock under their 2023 Inducement Plan, with options vesting over four years at an exercise price of $2.84.

Taysha Gene Therapies granted a new employee an option to purchase 90,000 shares of common stock under their 2023 Inducement Plan, with an exercise price of $2.63 and a 10-year term vesting over four years.

Taysha Gene Therapies announced details for three oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting, covering updates on its TSHA-102 clinical program for Rett syndrome and a symposium on natural history data.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced the pricing of a public offering of its common stock and pre-funded warrants, expected to raise approximately $200 million.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted a new employee an option to purchase 45,000 shares of the company's common stock as an inducement for their employment.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted stock options to three new employees as an inducement to join the company. The options have a 10-year term and will vest over four years.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted stock options to three new employees as an inducement for their employment. The options have a 10-year term and will vest over four years.

Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it granted a new employee an option to purchase 152,000 shares of the company's common stock as an inducement for their employment.